Hydroxichloroquine for COVID-19 infection: Do we have a final word after one year?
Eur J Intern Med
; 94: 4-5, 2021 12.
Article
in English
| MEDLINE | ID: covidwho-1482562
ABSTRACT
The results presently available from randomised clinical trials and their meta-analysis indicate that Hydroxychloroquine is not associated in COVID-19 patients with either decreased mortality or clinical worsening. Thus, the use of Hydroxychloroquine in COVID-19 patients cannot at present be encouraged. However, the hypothesis that Hydroxychloroquine might have a beneficial role in subgroups of patients at low risk and/or when used at low dosage (≤ 400 mg/day) deserves to be tested in large, well designed randomised clinical trials.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
COVID-19
Type of study:
Experimental Studies
/
Prognostic study
/
Randomized controlled trials
/
Reviews
Limits:
Humans
Language:
English
Journal:
Eur J Intern Med
Journal subject:
Internal Medicine
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS